Cargando…

Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial

Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that “oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallimann, Theo, Hall, Caroline H. T., Colgan, Sean P., Glover, Louise E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145094/
https://www.ncbi.nlm.nih.gov/pubmed/33922654
http://dx.doi.org/10.3390/nu13051429
_version_ 1783697100082511872
author Wallimann, Theo
Hall, Caroline H. T.
Colgan, Sean P.
Glover, Louise E.
author_facet Wallimann, Theo
Hall, Caroline H. T.
Colgan, Sean P.
Glover, Louise E.
author_sort Wallimann, Theo
collection PubMed
description Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that “oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular energy precursor, is likely to be effective in inducing a favorable response and/or remission in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and/or Crohn’s disease”. A current pilot clinical trial that incorporates the use of oral Cr at a dose of 2 × 7 g per day, over an initial period of 2 months in conjunction with ongoing therapies (NCT02463305) will be informative for the proposed larger, more long-term Cr supplementation study of 2 × 3–5 g of Cr per day for a time of 3–6 months. This strategy should be insightful to the potential for Cr in reducing or alleviating the symptoms of IBD. Supplementation with chemically pure Cr, a natural nutritional supplement, is well tolerated not only by healthy subjects, but also by patients with diverse neuromuscular diseases. If the outcome of such a clinical pilot study with Cr as monotherapy or in conjunction with metformin were positive, oral Cr supplementation could then be used in the future as potentially useful adjuvant therapeutic intervention for patients with IBD, preferably together with standard medication used for treating patients with chronic ulcerative colitis and/or Crohn’s disease.
format Online
Article
Text
id pubmed-8145094
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81450942021-05-26 Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial Wallimann, Theo Hall, Caroline H. T. Colgan, Sean P. Glover, Louise E. Nutrients Review Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that “oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular energy precursor, is likely to be effective in inducing a favorable response and/or remission in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and/or Crohn’s disease”. A current pilot clinical trial that incorporates the use of oral Cr at a dose of 2 × 7 g per day, over an initial period of 2 months in conjunction with ongoing therapies (NCT02463305) will be informative for the proposed larger, more long-term Cr supplementation study of 2 × 3–5 g of Cr per day for a time of 3–6 months. This strategy should be insightful to the potential for Cr in reducing or alleviating the symptoms of IBD. Supplementation with chemically pure Cr, a natural nutritional supplement, is well tolerated not only by healthy subjects, but also by patients with diverse neuromuscular diseases. If the outcome of such a clinical pilot study with Cr as monotherapy or in conjunction with metformin were positive, oral Cr supplementation could then be used in the future as potentially useful adjuvant therapeutic intervention for patients with IBD, preferably together with standard medication used for treating patients with chronic ulcerative colitis and/or Crohn’s disease. MDPI 2021-04-23 /pmc/articles/PMC8145094/ /pubmed/33922654 http://dx.doi.org/10.3390/nu13051429 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wallimann, Theo
Hall, Caroline H. T.
Colgan, Sean P.
Glover, Louise E.
Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title_full Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title_fullStr Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title_full_unstemmed Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title_short Creatine Supplementation for Patients with Inflammatory Bowel Diseases: A Scientific Rationale for a Clinical Trial
title_sort creatine supplementation for patients with inflammatory bowel diseases: a scientific rationale for a clinical trial
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145094/
https://www.ncbi.nlm.nih.gov/pubmed/33922654
http://dx.doi.org/10.3390/nu13051429
work_keys_str_mv AT wallimanntheo creatinesupplementationforpatientswithinflammatoryboweldiseasesascientificrationaleforaclinicaltrial
AT hallcarolineht creatinesupplementationforpatientswithinflammatoryboweldiseasesascientificrationaleforaclinicaltrial
AT colganseanp creatinesupplementationforpatientswithinflammatoryboweldiseasesascientificrationaleforaclinicaltrial
AT gloverlouisee creatinesupplementationforpatientswithinflammatoryboweldiseasesascientificrationaleforaclinicaltrial